The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Disease Control Rate at 8 Weeks Predicts Clinical Benefit in Advanced Non–Small-Cell Lung Cancer: Results From Southwest Oncology Group Randomized Trials
Abstract
Purpose: Tumor shrinkage categorized as complete response (CR) or partial response (PR) is a fundamental efficacy measure for new cancer treatments and often considered a surrogate for overall survival. However, for any given treatment, many more patients typically achieve stable disease (SD) or have progressive disease (PD) than achieve response. We hypothesized that PD (or its converse, disease control rate [DCR], consisting of CR, PR, SD) is a stronger predictor of survival than response alone in advanced non–small-cell lung cancer (NSCLC), and that this determination might be assessable early on during therapy. Patients and Methods: Data from 984 NSCLC patients entered onto three randomized Southwest Oncology Group trials of platinum-based chemotherapy were pooled and subjected to Landmark survival analysis. Patients were categorized according to proportions alive at weeks 8, 14, and 20 after registration, as well as response status. Elements were fitted into a Cox proportional hazards model. Results: Tumor response (CR, PR) was seen in 260 patients (27%). Median time to response, time to progression, and survival time were 2.0, 4.3 and 8.9 months, respectively. Median survival times among patients with CR/PR, SD, or PD were 13.5, 8.4, and 3.1 months, respectively. Of 892 patients alive at week 8, DCR was 62%. Although CR/PR at week 8 was associated with longer survival (hazard ratio [HR] = 0.61; P < .001), DCR was superior in predicting survival (HR = 0.45; P < .0001). Conclusion: DCR at week 8 is a more powerful predictor of subsequent survival than is the traditional tumor response rate in advanced NSCLC and provides an early assessment of subsequent outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Research works printed but not linked: 15
- 10.1016/S0959-8049(02)00182-X · DOI
- 10.1200/JCO.2000.18.19.3390 · DOI · Paper page
- 10.1200/JCO.1990.8.9.1556 · DOI · Paper page
- 10.1200/JCO.1993.11.5.873 · DOI
- 10.1016/S0197-2456(83)80011-7 · doi:10.1016/s0197-2456(83)80011-7
- 10.1016/0021-9681(60)90137-5 · DOI · Paper page
- 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 · DOI · Paper page
- Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions, and toxicity criteria. Invest New Drugs 10:259,1992-253, · DOI · Paper page
- 10.1093/jnci/92.3.205 · DOI · Paper page
- 10.1200/JCO.2003.01.144 · DOI · Paper page
- 10.1056/NEJMc052173 · DOI
- 10.1200/JCO.2001.19.13.3210 · DOI · Paper page
- 10.1158/1078-0432.CCR-04-0002 · DOI
- 10.1200/JCO.2005.01.3771 · DOI
- 10.1200/JCO.1983.1.11.710 · DOI · Paper page
Cited by
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Kim, E. S., Herbst, R. S., Wistuba, I. I., Lee, J. J., Blumenschein, G. R., Tsao, A., Stewart, D. J., Hicks, M. E., Erasmus, J., Gupta, S., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0010 · Cited by 889
Linardou, H., Dahabreh, I. J., Kanaloupiti, D., Siannis, F., Bafaloukos, D., Kosmidis, P., Papadimitriou, C. A., & Murray, S. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70206-7 · Cited by 739
Wu, J.-Y., Yu, C.-J., Chang, Y.-C., Yang, C.-H., Shih, J.-Y., & Yang, P.-C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3408 · Cited by 463
Claret, L., Girard, P., Hoff, P. M., Van Cutsem, E., Zuideveld, K. P., Jorga, K., Fagerberg, J., & Bruno, R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.0807 · Cited by 272
Metadata
- Authors
- Lara, P. N., Redman, M. W., Kelly, K., Edelman, M. J., Williamson, S. K., Crowley, J. J., & Gandara, D. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-01-20
- Volume
- 26
- Issue
- 3
- Pages
- 463-467
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2099173339
- Cited by
- 182
- References
- 1
- FWCI
- 18.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Disease Control Rate at 8 Weeks Predicts Clinical Benefit in Advanced Non–Small-Cell Lung Cancer: Results From Southwest Oncology Group Randomized Trials. https://app.cochat.ai/papers/10.1200/jco.2007.13.0344
- The paper
- Lara, P. N., Redman, M. W., Kelly, K., Edelman, M. J., Williamson, S. K., Crowley, J. J., & Gandara, D. R. (2008). Disease Control Rate at 8 Weeks Predicts Clinical Benefit in Advanced Non–Small-Cell Lung Cancer: Results From Southwest Oncology Group Randomized Trials. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2007.13.0344
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.